Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). FDA accepted CorMedix’s sNDA for REZZAYO prophylaxis of invasive fungal disease, advancing the product toward potential label expansion.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA accepted CorMedix’s sNDA for REZZAYO prophylaxis of invasive fungal disease, advancing the product toward potential label expansion
- Expanded indication could support additional REZZAYO commercial opportunity beyond its current use
- FDA acceptance does not assure approval, with possible requests for data, review extensions, or narrower labeling
- Key catalysts: FDA review outcome, PDUFA action date, and potential launch timing with Mundipharma
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted REZZAYO’s supplemental NDA for invasive fungal disease prophylaxis with Priority Review
- PDUFA target action date in Q1 2027, creating a near-term regulatory catalyst
- Potential indication expands rezafungin into adults undergoing allogeneic HSCT, supported by Phase III ReSPECT results
- CorMedix targets promotional efforts in H2 2027 if approved, supporting potential commercial upside
- Approval remains uncertain, with FDA able to request additional data or narrower labeling
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.